CN101863998B - 修饰糖、其缀合物及其制备方法 - Google Patents

修饰糖、其缀合物及其制备方法 Download PDF

Info

Publication number: CN101863998B
Authority: CN; China
Prior art keywords: group; capsular saccharide; modified; hydrocarbon group; toxoid
Prior art date: 2002-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN2010101825535A

Other languages

English (en)

Chinese (zh)

Other versions

CN101863998A (zh

Inventor

A·吉亚诺齐

G·阿弗拉尼

F·诺莱利

P·科斯坦蒂诺

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

Novartis Vaccines and Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-30

Filing date

2003-09-01

Publication date

2012-08-29

2003-09-01 Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc

2010-10-20 Publication of CN101863998A publication Critical patent/CN101863998A/zh

2012-08-29 Application granted granted Critical

2012-08-29 Publication of CN101863998B publication Critical patent/CN101863998B/zh

2023-09-01 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000001720 carbohydrates Chemical class 0.000 title claims abstract description 55
238000004519 manufacturing process Methods 0.000 title claims description 4
235000000346 sugar Nutrition 0.000 claims abstract description 67
125000003172 aldehyde group Chemical group 0.000 claims abstract description 19
229910052799 carbon Inorganic materials 0.000 claims abstract description 14
241000921898 Neisseria meningitidis serogroup A Species 0.000 claims abstract description 13
108090000288 Glycoproteins Proteins 0.000 claims abstract description 12
102000003886 Glycoproteins Human genes 0.000 claims abstract description 12
125000002947 alkylene group Chemical group 0.000 claims abstract description 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 33
125000001183 hydrocarbyl group Chemical group 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 25
102000004169 proteins and genes Human genes 0.000 claims description 24
229960005486 vaccine Drugs 0.000 claims description 22
-1 amino compound Chemical class 0.000 claims description 21
125000000753 cycloalkyl group Chemical group 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 17
238000006268 reductive amination reaction Methods 0.000 claims description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
125000003118 aryl group Chemical group 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
239000003153 chemical reaction reagent Substances 0.000 claims description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
241000588650 Neisseria meningitidis Species 0.000 claims description 9
125000005842 heteroatom Chemical group 0.000 claims description 9
231100000699 Bacterial toxin Toxicity 0.000 claims description 7
239000000688 bacterial toxin Substances 0.000 claims description 7
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
239000000010 aprotic solvent Substances 0.000 claims description 6
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
230000004048 modification Effects 0.000 claims description 5
238000012986 modification Methods 0.000 claims description 5
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
230000001588 bifunctional effect Effects 0.000 claims description 4
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 4
108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
239000003638 chemical reducing agent Substances 0.000 claims description 3
238000003776 cleavage reaction Methods 0.000 claims description 3
GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 2
206010027202 Meningitis bacterial Diseases 0.000 claims description 2
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
201000009904 bacterial meningitis Diseases 0.000 claims description 2
VRAVWQUXPCWGSU-UHFFFAOYSA-N bis(1h-1,2,4-triazol-5-yl)methanone Chemical compound N1=CNN=C1C(=O)C=1N=CNN=1 VRAVWQUXPCWGSU-UHFFFAOYSA-N 0.000 claims description 2
XYCAAOUPBWVNPF-UHFFFAOYSA-N bis(2h-benzotriazol-4-yl)methanone Chemical compound C=1C=CC=2NN=NC=2C=1C(=O)C1=CC=CC2=C1N=NN2 XYCAAOUPBWVNPF-UHFFFAOYSA-N 0.000 claims description 2
239000000470 constituent Substances 0.000 claims description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 2
102000016607 Diphtheria Toxin Human genes 0.000 claims 2
239000012646 vaccine adjuvant Substances 0.000 claims 1
229940124931 vaccine adjuvant Drugs 0.000 claims 1
125000005647 linker group Chemical group 0.000 abstract description 12
230000002163 immunogen Effects 0.000 abstract description 4
102000036639 antigens Human genes 0.000 description 47
108091007433 antigens Proteins 0.000 description 47
239000000427 antigen Substances 0.000 description 43
150000008163 sugars Chemical class 0.000 description 29
150000004676 glycans Chemical class 0.000 description 27
229920001282 polysaccharide Polymers 0.000 description 27
239000005017 polysaccharide Substances 0.000 description 27
150000001299 aldehydes Chemical class 0.000 description 12
229920001542 oligosaccharide Polymers 0.000 description 12
150000002482 oligosaccharides Chemical class 0.000 description 12
239000002671 adjuvant Substances 0.000 description 9
102000014914 Carrier Proteins Human genes 0.000 description 8
108010078791 Carrier Proteins Proteins 0.000 description 8
150000002772 monosaccharides Chemical group 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
241000700605 Viruses Species 0.000 description 6
235000014633 carbohydrates Nutrition 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
201000005702 Pertussis Diseases 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
206010013023 diphtheria Diseases 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000007949 saponins Chemical class 0.000 description 5
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
150000001718 carbodiimides Chemical class 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000000873 masking effect Effects 0.000 description 4
239000002245 particle Substances 0.000 description 4
229930182490 saponin Natural products 0.000 description 4
235000017709 saponins Nutrition 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
108010039939 Cell Wall Skeleton Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000606768 Haemophilus influenzae Species 0.000 description 3
201000009906 Meningitis Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004520 cell wall skeleton Anatomy 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
229940047650 haemophilus influenzae Drugs 0.000 description 3
230000003053 immunization Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
229940066429 octoxynol Drugs 0.000 description 3
229920002113 octoxynol Polymers 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
102100034452 Alternative prion protein Human genes 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
QOFRNSMLZCPQKL-KTIIIUPTSA-N CCN(CC)CC.CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)NCCO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC Chemical compound CCN(CC)CC.CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)NCCO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC QOFRNSMLZCPQKL-KTIIIUPTSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
241000193163 Clostridioides difficile Species 0.000 description 2
108010060123 Conjugate Vaccines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
101710154643 Filamentous hemagglutinin Proteins 0.000 description 2
241000710831 Flavivirus Species 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000872931 Myoporum sandwicense Species 0.000 description 2
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000193985 Streptococcus agalactiae Species 0.000 description 2
241000193998 Streptococcus pneumoniae Species 0.000 description 2
241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940031670 conjugate vaccine Drugs 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000010008 shearing Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
229940031000 streptococcus pneumoniae Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241001118702 Border disease virus Species 0.000 description 1
241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241001647372 Chlamydia pneumoniae Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
241000710777 Classical swine fever virus Species 0.000 description 1
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
101150029115 HOPX gene Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000702617 Human parvovirus B19 Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
241001644525 Nastus productus Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
101150000679 OPTN gene Proteins 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000605862 Porphyromonas gingivalis Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
229940124875 RabAvert Drugs 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
101710084578 Short neurotoxin 1 Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
101710182223 Toxin B Proteins 0.000 description 1
101710182532 Toxin a Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000710886 West Nile virus Species 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
KDJVUTSOHYQCDQ-UHFFFAOYSA-N carbamic acid;1h-imidazole Chemical compound NC([O-])=O.[NH2+]1C=CN=C1 KDJVUTSOHYQCDQ-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
229930186900 holotoxin Natural products 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000000743 hydrocarbylene group Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
238000002715 modification method Methods 0.000 description 1
230000001459 mortal effect Effects 0.000 description 1
230000003232 mucoadhesive effect Effects 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
229940047091 other immunostimulants in atc Drugs 0.000 description 1
238000005949 ozonolysis reaction Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
108010021711 pertactin Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
125000005592 polycycloalkyl group Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
150000003555 thioacetals Chemical class 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Virology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN2010101825535A 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法 Expired - Fee Related CN101863998B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0220198.6		2002-08-30
GBGB0220198.6A GB0220198D0 (en)	2002-08-30	2002-08-30	Modified saccharides,conjugates thereof and their manufacture

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN038237245A Division CN1688343B (zh)	2002-08-30	2003-09-01	修饰糖、其缀合物及其制备方法

Publications (2)

Publication Number	Publication Date
CN101863998A CN101863998A (zh)	2010-10-20
CN101863998B true CN101863998B (zh)	2012-08-29

Family

ID=9943241

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN2010101825535A Expired - Fee Related CN101863998B (zh)	2002-08-30	2003-09-01	修饰糖、其缀合物及其制备方法
CN038237245A Expired - Fee Related CN1688343B (zh)	2002-08-30	2003-09-01	修饰糖、其缀合物及其制备方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN038237245A Expired - Fee Related CN1688343B (zh)	2002-08-30	2003-09-01	修饰糖、其缀合物及其制备方法

Country Status (16)

Country	Link
US (2)	US8895516B2 (2)
EP (1)	EP1534342B1 (2)
JP (2)	JP5268222B2 (2)
CN (2)	CN101863998B (2)
AT (1)	ATE319481T1 (2)
AU (1)	AU2003260921B2 (2)
BR (1)	BR0314089A (2)
CA (1)	CA2497167C (2)
DE (1)	DE60303961T2 (2)
DK (1)	DK1534342T3 (2)
ES (1)	ES2260682T3 (2)
GB (1)	GB0220198D0 (2)
MX (1)	MXPA05002315A (2)
NZ (1)	NZ538703A (2)
RU (2)	RU2005108992A (2)
WO (1)	WO2004019992A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11147866B2 (en)	2016-09-02	2021-10-19	Sanofi Pasteur Inc.	Neisseria meningitidis vaccine

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) *	2002-08-30	2002-10-09	Chiron Spa	Modified saccharides,conjugates thereof and their manufacture
EP2172213B1 (en)	2003-01-30	2013-04-03	Novartis AG	Injectable vaccines against multiple meningococcal serogroups
WO2005051429A2 (en) *	2003-11-19	2005-06-09	Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Targeted conjugates with a modified saccharide linker
MX2007013881A (es)	2005-05-06	2008-10-22	Novartis Vaccines & Diagnostic	Inmunogenos para vacunas de meningitides-a.
KR101515078B1 (ko) *	2005-12-22	2015-04-24	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) *	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
AU2014200640B2 (en) *	2007-01-11	2016-06-16	Glaxosmithkline Biologicals Sa	Modified saccharides
WO2010027499A2 (en)	2008-09-05	2010-03-11	University Of Massachusetts Medical School	Methods, compositions and vaccines relating to neisseria meningitidis antibodies
SA110310528B1 (ar)	2009-06-22	2014-07-02	Wyeth Llc	التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en)	2009-06-22	2014-11-27	Wyeth Llc	Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE034251T2 (en) *	2009-10-30	2018-02-28	Glaxosmithkline Biologicals Sa	Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN107913396B (zh)	2010-08-23	2022-03-08	惠氏有限责任公司	脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en)	2010-09-10	2015-03-26	Wyeth Llc	Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en)	2012-03-09	2023-10-02	Pfizer	Neisseria meningitidis compositions and methods thereof
CN102861326A (zh) *	2012-09-19	2013-01-09	天津康希诺生物技术有限公司	流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en)	2013-03-08	2014-09-12	Pfizer Inc.	Immunogenic fusion polypeptides
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
ES2701169T3 (es) *	2014-02-14	2019-02-21	Pfizer	Conjugados glucoproteicos inmunogénicos
WO2016132294A1 (en)	2015-02-19	2016-08-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
WO2016170186A1 (en) *	2015-04-23	2016-10-27	Synaffix B.V.	PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
JP2019508468A (ja) *	2016-03-15	2019-03-28	エムエスディーウェルカムトラストヒルマンラボラトリーズプライベートリミテッドＭｓｄＷｅｌｌｃｏｍｅＴｒｕｓｔＨｉｌｌｅｍａｎＬａｂｏｒａｔｏｒｉｅｓＰｖｔ．Ｌｔｄ．	新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
AU2018215585B2 (en)	2017-01-31	2022-03-17	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) *	2017-02-24	2025-05-20	メルク・シャープ・アンド・ドーム・エルエルシー	肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
MX394768B (es)	2017-09-07	2025-03-21	Merck Sharp & Dohme Llc	Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
MX394767B (es)	2017-09-07	2025-03-24	Merck Sharp & Dohme Llc	Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2020182635A1 (en) *	2019-03-08	2020-09-17	Glaxosmithkline Biologicals Sa	Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
WO2021059181A1 (en)	2019-09-27	2021-04-01	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5929049A (en) *	1997-08-08	1999-07-27	Dade Behring Marburg Gmbh	Polysaccharide conjugates of biomolecules
CN1688343B (zh) *	2002-08-30	2010-09-08	诺华疫苗和诊断有限公司	修饰糖、其缀合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2427341A1 (fr) *	1978-06-02	1979-12-28	Delalande Sa	Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) *	1990-03-15	1994-12-12	Tanabe Seiyaku Co	Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
US5698526A (en) *	1993-12-28	1997-12-16	Pfizer Inc.	Steroidal glycosides
WO1995029927A2 (en) *	1994-05-02	1995-11-09	Biomira, Inc.	Process for preparation of glycosides of tumor-associated carbohydrate antigens
US6472506B1 (en) *	1997-01-21	2002-10-29	Aventis Pasteur S.A.	Polysaccharide-peptide-conjugates
JP4182269B2 (ja) *	1997-08-08	2008-11-19	ベーリングウエルケ、アクティエンゲゼルシャフト	生体分子のポリサッカライド接合体
US5952454A (en) *	1997-12-12	1999-09-14	The United States Of America As Represented By The Department Of Health And Human Services	Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es)	2002-03-26	2017-06-09	Glaxosmithkline Biologicals Sa	Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento

2002
- 2002-08-30 GB GBGB0220198.6A patent/GB0220198D0/en not_active Ceased
2003
- 2003-09-01 US US10/526,124 patent/US8895516B2/en not_active Expired - Fee Related
- 2003-09-01 DE DE60303961T patent/DE60303961T2/de not_active Expired - Lifetime
- 2003-09-01 DK DK03791149T patent/DK1534342T3/da active
- 2003-09-01 AT AT03791149T patent/ATE319481T1/de active
- 2003-09-01 AU AU2003260921A patent/AU2003260921B2/en not_active Ceased
- 2003-09-01 BR BR0314089-0A patent/BR0314089A/pt not_active Application Discontinuation
- 2003-09-01 ES ES03791149T patent/ES2260682T3/es not_active Expired - Lifetime
- 2003-09-01 CA CA2497167A patent/CA2497167C/en not_active Expired - Fee Related
- 2003-09-01 WO PCT/IB2003/004194 patent/WO2004019992A1/en not_active Ceased
- 2003-09-01 NZ NZ538703A patent/NZ538703A/en not_active IP Right Cessation
- 2003-09-01 EP EP03791149A patent/EP1534342B1/en not_active Expired - Lifetime
- 2003-09-01 CN CN2010101825535A patent/CN101863998B/zh not_active Expired - Fee Related
- 2003-09-01 JP JP2004532625A patent/JP5268222B2/ja not_active Expired - Fee Related
- 2003-09-01 MX MXPA05002315A patent/MXPA05002315A/es active IP Right Grant
- 2003-09-01 RU RU2005108992/04A patent/RU2005108992A/ru unknown
- 2003-09-01 CN CN038237245A patent/CN1688343B/zh not_active Expired - Fee Related
2008
- 2008-12-19 RU RU2008150551/13A patent/RU2531909C2/ru not_active IP Right Cessation
2011
- 2011-10-17 JP JP2011228229A patent/JP5314745B2/ja not_active Expired - Fee Related
2014
- 2014-10-23 US US14/521,761 patent/US20150166593A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5929049A (en) *	1997-08-08	1999-07-27	Dade Behring Marburg Gmbh	Polysaccharide conjugates of biomolecules
CN1688343B (zh) *	2002-08-30	2010-09-08	诺华疫苗和诊断有限公司	修饰糖、其缀合物及其制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11147866B2 (en)	2016-09-02	2021-10-19	Sanofi Pasteur Inc.	Neisseria meningitidis vaccine
US11707514B2 (en)	2016-09-02	2023-07-25	Sanofi Pasteur Inc.	Neisseria meningitidis vaccine
US12611451B2 (en)	2016-09-02	2026-04-28	Sanofi Vaccines US Inc.	Neisseria meningitidis vaccine

Also Published As

Publication number	Publication date
BR0314089A (pt)	2005-11-16
WO2004019992A1 (en)	2004-03-11
CA2497167A1 (en)	2004-03-11
CN101863998A (zh)	2010-10-20
EP1534342B1 (en)	2006-03-08
CN1688343A (zh)	2005-10-26
NZ538703A (en)	2006-09-29
JP5268222B2 (ja)	2013-08-21
JP5314745B2 (ja)	2013-10-16
EP1534342A1 (en)	2005-06-01
AU2003260921A1 (en)	2004-03-19
MXPA05002315A (es)	2005-06-08
CA2497167C (en)	2011-07-12
DK1534342T3 (da)	2006-07-10
CN1688343B (zh)	2010-09-08
DE60303961D1 (de)	2006-05-04
DE60303961T2 (de)	2006-10-26
JP2006511465A (ja)	2006-04-06
AU2003260921B2 (en)	2008-03-06
US8895516B2 (en)	2014-11-25
RU2008150551A (ru)	2010-06-27
ES2260682T3 (es)	2006-11-01
US20150166593A1 (en)	2015-06-18
GB0220198D0 (en)	2002-10-09
US20060263390A1 (en)	2006-11-23
ATE319481T1 (de)	2006-03-15
RU2005108992A (ru)	2005-11-10
RU2531909C2 (ru)	2014-10-27
JP2012017342A (ja)	2012-01-26

Legal Events

Date	Code	Title	Description
2010-10-20	C06	Publication
2010-10-20	PB01	Publication
2010-12-01	C10	Entry into substantive examination
2010-12-01	SE01	Entry into force of request for substantive examination
2012-08-29	C14	Grant of patent or utility model
2012-08-29	GR01	Patent grant
2017-08-18	TR01	Transfer of patent right	Effective date of registration: 20170801 Address after: Belgium Sutter Rixon Patentee after: Glazo Smithkline Beecham Biologicals S. A. Address before: Italy Siena Patentee before: Novartis Vaccines & Diagnostic
2017-08-18	TR01	Transfer of patent right
2019-08-16	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20120829 Termination date: 20180901
2019-08-16	CF01	Termination of patent right due to non-payment of annual fee

Publication	Publication Date	Title
CN101863998B (zh)	2012-08-29	修饰糖、其缀合物及其制备方法
EP1777236B1 (en)	2016-11-30	Modified saccharides having improved stability in water for use as a medicament
EP2184071B1 (en)	2016-08-31	Capsular polysaccharide solubilisation and combination vaccines
EP2258717A2 (en)	2010-12-08	Variant form of meningococcal NadA
CN100491403C (zh)	2009-05-27	具有改善的水中稳定性的修饰的糖类
AU2003216633B2 (en)	2010-02-11	Modified saccharides having improved stability in water